Journal of Vascular Surgery
Volume 31, Issue 5 , Pages 1066-1076 , May 2000

Potential problems with industry-supported clinical research

References 

  1. Shimm DS, Spece RG. Discovering the ethical requirements of physicians' roles in the service of conflicting interests as healers and as citizens. In:  Spece RG,  Shimm DS,  Buchanan AE editor. Conflict of interest in clinical practice and research. New York: Oxford University Press; 1996;
  2. Shimm DS, Spece RG. An introduction to conflict of interest in clinical research. In:  Spece RG,  Shimm DS,  Buchanan AE editor. Conflict of interest in clinical practice and research. New York: Oxford University Press; 1996;
  3. Council on Scientific Affairs and Council on Ethical and Judicial Affairs, American Medical Association . Conflicts of interest in medical center/industry research relationships. JAMA. 1990;263:2790–2793
  4. King RT. The doctor as a stockholder. The Wall Street Journal 1999. 1999 May 5;Sect A:1
  5. Eichenwald K, Kolata G. Hidden interest—a special report: when physicians double as entrepreneurs. New York Times. 1999 Nov 30; Financial/Business sect
  6. Phillips RA, Hoey J. Constraints of interest: lessons at the Hospital for Sick Children. Can Med Assoc J. 1998;159:955–957
  7. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McLelland RA, et al.  Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417–423
  8. Etchells E, McLeod RS, Greets W, et al.  Economic analysis of low-dose heparin vs. the low-molecular–weight heparin Enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch Intern Med. 1999;159:1221–1228
  9. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–145
  10. Beebe HG. Scientific evidence demonstrating the safety of carotid angioplasty and stenting: do we have enough to draw conclusions yet?. J Vasc Surg. 1998;27:788–790
  11. Hobson RW. Status of carotid angioplasty and stenting trials. J Vasc Surg. 1998;27:791
  12. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity . The STILE trial. Ann Surg. 1994;220:251–256
  13. Shimm D, Spece R. Industry reimbursement for entering patients into clinical trials: legal and ethical issues. Ann Intern Med. 1991;115:148–151
  14. Richter GM. Results of a randomized trial of iliac PTA vs primary stenting. [abstract] J Vasc Interv Radiol. 1993;4:30
  15. Jones DN Jr, Nehler MR, Merli G, Durham JD, Hiatt WR, Whitehill TA, et al. The incidence of adequate surveillance exams in multicenter trial of deep venous thrombosis prophylaxis. Abstract submitted and accepted for the American Venous Forum 1998 meeting. Presentation withdrawn.
  16. Sternburgh WC, Money SR. Hospital cost of endovascular versus open repair of abdominal aortic aneurysms: a multicenter study. J Vasc Surg. 2000;31:237–244
  17. Rutherford RB. Problems with the dissemination of up-to-date information on the results of endograft repair for abdominal aortic aneurysm. J Vasc Surg. 1999;29:1167–1169
  18. Bernhard VM. Development of the endovascular prosthesis. Bull Am Coll Surg. 1996;81:20–21
  19. Riepe G, Heilberger P, Umscheid T, Chafke N, Raithel D, et al.  Frame dislocation of body middle rings in endovascular stent tube grafts. Eur J Vasc Endovasc Surg. 1999;17:28–34
  20. Buth J, Harris PL, Miahle C. Eurostar endovascular registry: success rates, complications, significance of endoleaks, and is suture breakage in stent grafts important? Montefiore Symposium on Current Critical Problems, New Horizons and Techniques in Vascular and Endovascular. Surgery. 1998 Nov 19;
  21. Harris PR, Buth J. Regarding “problems with the dissemination of up-to-date information on the results of endograft repair for abdominal aortic aneurysm”. [letter] J Vasc Surg. 1999;30:767–768
  22. Rutherford RB. Reply to letter regarding “problems with the dissemination of up-to-date information on the results of endograft repair for abdominal aortic aneurysms”. J Vasc Surg. 1999;30:768–769
  23. Krohg-Sørensen K, Brekke M, Drolsum A, Kvernebo K. Periprosthetic leak and rupture after endovascular repair of abdominal aortic aneurysm: the significance of device design for long-term results. J Vasc Surg. 1999;29:1152–1158
  24. Politz JK, Newman VS, Stewart MT. Late abdominal aortic aneurysm rupture after AneuRx repair: a report of three cases. J Vasc Surg. 2000;31:599–606
  25. Zarins CK, White RA, Fogarty TJ. Aneurysm rupture after endovascular repair using the AneuRx stent graft. J Vasc Surg. 2000;31:960–970
  26. Clarke WM, Raps EC, Tong DC, Kelley RE. Cervene in acute ischemic stroke: results of a Phase III randomized efficacy study. [abstract] Stroke. 1999;30:234
  27. Goldstein LB, Brott TG, Kothari RU, Smith WS. Clinical stroke trials: guarding against bias. Stroke. 1999;30:1165–1166
  28. Krupski WC, Reilly LM, Perez S, Moss KM, Crombleholme PA, Rapp JH. A prospective randomized trial of autologous platelet derived wound healing factors for the treatment of chronic non-healing wounds: a preliminary report. J Vasc Surg. 1991;14:526–532
  29. Loss LE, Deitrick GA, Duff RG. Regarding “a prospective randomized trial of autologous platelet derived wound healing factors for the treatment of chronic non-healing wounds: a preliminary report”. [letter] J Vasc Surg. 1992;16:125–126
  30. Glover JL. Regarding “A prospective randomized trial of autologous platelet derived wound healing factors for the treatment of chronic non-healing wounds: a preliminary report”. [letter] J Vasc Surg. 1992;16:124–125
  31. Dosick SM. Regarding “A prospective randomized trial of autologous platelet derived wound healing factors for the treatment of chronic non-healing wounds: a preliminary report”. [letter] J Vasc Surg. 1992;16:125
  32. Krupski WC. Reply to letters to the editor regarding “A prospective randomized trial of autologous platelet derived wound healing factors for the treatment of chronic non-healing wounds: a preliminary report”. J Vasc Surg. 1992;16:126–128
  33. Hailey D. Scientific harassment by pharmaceutical companies: time to stop. CMAJ. 2000;162:212–213
  34. Rennie D. Fair conduct and fair reporting of clinical trials. JAMA. 1999;282:1766–1768
  35. Horton R, Smith R. Time to register randomised trials. [editorial] BMJ. 1999;319:865–866

☆ Competition of interest: currently none. Recent past: co-chair of a transatlantic intersocietal consensus on peripheral arterial occlusive disease (TASC) supported by an unrestricted educational grant from Schering AG, Berlin, Co-principal investigator of a completed trial of oral Iloprost in chronic critical limb ischemia, supported by Berlex, consultant on the design of clinical trials of the evaluation of thrombolytic agents (Abbott, Amigen); PI and member of the Scientific Advisory Board of EVT during the phase I trials (R.B.R.).

☆☆ Competition of interest: nil (K.W.J.).

★ Reprint requests: Dr K. Wayne Johnston, Editorial Office, Toronto General Hospital, 5 Eaton Room 312, 200 Elizabeth St, Toronto, Ontario, M5G 2C4, Canada.

★★ J Vasc Surg 2000;31:1066-76.

PII: S0741-5214(00)00029-X

doi: 10.1067/mva.2000.106031

Journal of Vascular Surgery
Volume 31, Issue 5 , Pages 1066-1076 , May 2000

Article Tools

* Image Usage & Resolution